BIOMAT Database Logo BIOMAT Database Logo

Signaling networks associated with BCR-ABL-dependent transformation. 2009

Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Molecular Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA. Lori.Hazlehurst@moffitt.org

BACKGROUND The fusion protein BCR-ABL results in constitutive tyrosine kinase activity. It also affects downstream targets as well as the subcellular location of the normally tightly regulated Abl tyrosine kinase. METHODS The authors review the current knowledge concerning the signaling networks associated with BCR-ABL-dependent transformation. RESULTS Although BCR-ABL is considered a single genetic change, the dysregulated tyrosine kinase activates a network of signals that contributes to cytokine-independent growth, resistance to apoptosis, and genetic instability. CONCLUSIONS The effectiveness of BCR-ABL-dependent transformation of hematopoietic stem cells is due not to a single pathway but rather to the culmination of a network of signaling pathways.

UI MeSH Term Description Entries
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016044 Fusion Proteins, bcr-abl Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC. Oncogene Protein p190(bcr-abl),Oncogene Protein p210(bcr-abl),bcr-abl Fusion Protein,bcr-abl Fusion Proteins,Bcr-Abl Tyrosine Kinase,Oncogene Protein p185(bcr-abl),Oncogene Protein p230(bcr-abl),p185(bcr-abl) Fusion Proteins,p190(bcr-abl) Fusion Proteins,p210(bcr-abl) Fusion Proteins,p230(bcr-abl) Fusion Proteins,Bcr Abl Tyrosine Kinase,Fusion Protein, bcr-abl,Fusion Proteins, bcr abl,Kinase, Bcr-Abl Tyrosine,Protein, bcr-abl Fusion,Tyrosine Kinase, Bcr-Abl,bcr abl Fusion Protein,bcr abl Fusion Proteins

Related Publications

Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
CRKL binding to BCR-ABL and BCR-ABL transformation.
March 1999, Leukemia & lymphoma,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Malignant transformation by abl and BCR/ABL.
January 1992, Cancer treatment and research,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
November 1998, The Journal of biological chemistry,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
January 1997, Blood,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
October 1995, Molecular and cellular biology,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Signal transduction pathways involved in BCR-ABL transformation.
June 1997, Bailliere's clinical haematology,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Mechanisms of transformation by the BCR/ABL oncogene.
April 2001, International journal of hematology,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
July 1991, Cell,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Bcr-Abl induces autocrine IGF-1 signaling.
June 2008, Oncogene,
Lori A Hazlehurst, and Nadine N Bewry, and Rajesh R Nair, and Javier Pinilla-Ibarz
Bcr/Abl associated leukemogenesis in bcr null mutant mice.
April 1998, Oncogene,
Copied contents to your clipboard!